Rafael Fonseca, MD

Experts on multiple myeloma look to the future treatment landscape and discuss exciting updates presented at the 2024 ASCO Annual Meeting, highlighting belantamab mafodotin and combination therapies.

Samer Al'Hadidi, MD, provides a comprehensive overview of adverse event management practices for patients with multiple myeloma who receive CAR T-cell therapy.

Hans Lee, MD, discusses recent updates presented at ASCO 2024 surrounding cilta-cel CAR T-cell therapy in relapsed/refractory multiple myeloma.

Myeloma specialists discuss considerations they consider when determining how they sequence CAR T-cell therapies and bispecific antibodies.

Following ASCO 2024, Samer Al'Hadidi, MD, discusses recent updates from the PERSEUS trial evaluating the role of testing for minimal residual disease (MRD) in guiding treatment for relapsed/refractory multiple myeloma.

Experts on multiple myeloma provide comprehensive insights on treatment spacing and step-up dosing practices and discuss the long-term utilization of bispecific antibodies.

The expert panel shares clinical insights on sequencing CAR T-cell therapies and bispecific antibodies for patients with relapsed/refractory multiple myeloma.

Naresh Bumma, MD, and Hans Lee, MD, recap recent updates on the MagnetisMM-30 an MagnetisMM-32 studies investigating elranatamab, a BCMA-directed bispecific antibody.

Samer Al'Hadidi, MD, provides an overview of recent updates presented at ASCO 2024 from the MajesTEC-1 trial evaluating teclistamab in patients with relapsed/refractory multiple myeloma.

Hans Lee, MD, discusses recent updates from the MonumenTAL-2 study investigating talquetamab in patients with relapsed/refractory multiple myeloma.

Focusing on recent approvals in earlier lines of relapsed/refractory multiple myeloma, the panel has a comprehensive discussion on the CARTITUDE-4 and KarMMa-3 studies and shares clinical insights on administering CAR T-cell therapy and monitoring patients.

A panel of experts on multiple myeloma introduce themselves and discuss recent data presented on the phase 3 IMROZ trial for transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM).

The panel concludes the discussion by offering future perspectives on the evolving treatment landscape in multiple myeloma, highlighting exciting developments and ongoing research.

Continuing discussion centered on a patient case, the panel discusses bispecific antibody combinations and the role of BCMA-targeting CAR T-cell therapies in relapsed/refractory multiple myeloma.

Adriana Rossi, MD, presents the case of a 60-year-old patient with stage III kappa light chain multiple myeloma, and members of the panel provide their initial impressions.

The panel discusses the utilization of CAR T-cell therapy for patients with multiple myeloma, highlighting treatment selection, sequencing, and insurance considerations.

Binod Dhakal, MD, presents the case of a 66-year-old patient with IgG kappa multiple myeloma, and the panel discusses treatment considerations and decisions.

Surbhi Sidana, MD, provides clinical insights on treatment sequencing strategies for patients with relapsed/refractory multiple myeloma.

Myeloma specialists discuss clinical trials investigating CAR T-cell therapies in patients with relapsed/refractory disease.

The panel discusses recent updates on bispecific antibodies for patients with relapsed/refractory multiple myeloma, highlighting studies investigating talquetamab, teclistamab, and elranatamab.

A panel of experts on multiple myeloma introduce themselves and discuss recent CAR T-cell therapy approvals in earlier treatment lines for patients with relapsed/refractory disease.

Experts from Mayo Clinic and The University of Texas MD Anderson Cancer Center discuss results from multiple myeloma trials presented at the 2023 American Society of Clinical Oncology Annual Meeting and how they may apply to clinical practice.

Closing out their panel on bispecifics in relapsed/refractory multiple myeloma, key opinion leaders share closing thoughts and hopes for the future treatment landscape.

Expert panelists from Mayo Clinic discuss their approach for the use of BCMA and non-BCMA targeting bispecifics, respectively, in patients with relapsed/refractory multiple myeloma.

Focused discussion on the mSMART guidelines for monitoring and managing adverse events associated with bispecific therapies in patients being treated for relapsed/refractory multiple myeloma.

A panel of key opinion leaders from Mayo Clinic reflect on optimizing use of bispecifics in relapsed/refractory multiple myeloma, reviewing step-up dosing, administration, and followup strategies.

Comprehensive insights from experts in Mayo Clinic on the selection and sequencing of CAR T cell therapy or bispecifics, respectively, in patients with relapsed/refractory multiple myeloma.

Before closing out the panel’s review of clinical data behind bispecifics in relapsed/refractory multiple myeloma, Morie Gertz, MD, highlights use of cevostamab therapy in this setting.

Shared insight from Rafael Fonseca, MD, on data from MonumenTAL-1 and the use of talquetamab therapy in patients with relapsed/refractory multiple myeloma.

Expert perspectives from Joselle Cook, MBBS, on use of elranatamab in relapsed/refractory multiple myeloma based on data from the MagnetisMM-1 trial.